

Resource Summary Report

Generated by [NIF](#) on Sep 9, 2026

OCI-My5

RRID:CVCL_E332

Type: Cell Line

Proper Citation

RRID:CVCL_E332

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_E332

Proper Citation: RRID:CVCL_E332

Description: Cell line OCI-My5 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Sex unspecified

Disease: Plasma cell myeloma

Defining Citation: [PMID:1912582](#), [PMID:3137236](#), [PMID:8138440](#), [PMID:8943038](#), [PMID:10936422](#), [PMID:11157491](#), [PMID:17692805](#), [PMID:18647998](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:32123307](#)

Comments: Characteristics: Produces IgA lambda (PubMed=3137236)., Population: Caucasian., From: Ontario Cancer Institute (OCI); Toronto; Canada., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OCI-My5

Synonyms: OCI-MY5, OCI-My 5, OCIMy5, OCIMY5, MY5

Cross References: BioSample:SAMN10989616, cancercellines:CVCL_E332, Cell_Model_Passport:SIDM01876, Cosmic:720791, Cosmic:2081401, Cosmic:2302416, Cosmic:2367261, DepMap:ACH-000854, GEO:GSM1374794, Wikidata:Q54931788

ID: CVCL_E332

Record Creation Time: 20220427T221355+0000

Ratings and Alerts

No rating or validation information has been found for OCI-My5.

No alerts have been found for OCI-My5.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Cholujova D, et al. (2026) Anti-myeloma activity of the CXCR4 antagonist WZ811. Journal of molecular medicine (Berlin, Germany), 104(1), 45.

Bolomsky A, et al. (2024) IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. Cancer cell, 42(7), 1185.

Yu Z, et al. (2022) Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma. EBioMedicine, 78, 103950.